Clinical Trial

A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study aims to generate additional safety data on the propellant component of the reformulated product by comparing metered dose inhaler (MDIs) containing HFA-152a (test) with HFA-134a (reference).
Trial Details
NCT Number NCT07645248
Lead Sponsor GlaxoSmithKline
Conditions Asthma
Enrollment 110 participants
Start Date 2026-09-15
Primary Completion 2027-02-25 (estimated)
Study Completion 2027-02-25 (estimated)
Updated on ClinicalTrials.gov 2026-06-12